Can a Three-Drug attack shrink stomach cancer in the abdomen?
NCT ID NCT06914687
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This trial tests whether combining an immunotherapy drug (tislelizumab) with standard chemotherapy and heated chemotherapy delivered directly into the abdomen can shrink tumors and improve survival in people with stomach cancer that has spread to the lining of the abdomen. The study enrolls 30 adults aged 18 to 75 with confirmed peritoneal metastases. Researchers will measure how many patients survive for one year and how many become eligible for complete surgical removal of their cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of the immunotherapy drug tislelizumab, chemotherapy drugs S-1 and oxaliplatin, and heated chemotherapy (docetaxel or paclitaxel) delivered directly into the abdomen
- What this could lead to
- If successful, this approach could offer a new treatment option for people with stomach cancer that has spread to the lining of the abdomen, potentially improving survival and increasing the chance of successful surgery.
- What could go wrong
- This is a small, early-phase trial with only 30 participants and no comparison group, so results may not apply broadly. The combination of multiple strong treatments also raises the risk of serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Hospital
Shanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can an immunotherapy combo shrink stomach tumors before surgery?
- Can adding immunotherapy to chemotherapy improve gastric cancer outcomes?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Can a smart drug home in on Hard-to-Treat cancers?